Human B Cell-Derived Lymphoblastoid Cell Lines Constitutively Produce Fas Ligand and Secrete MHCII+FasL+ Killer Exosomes by Matthew W. Klinker et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ORIGINAL RESEARCH ARTICLE
published: 02 April 2014
doi: 10.3389/fimmu.2014.00144
Human B cell-derived lymphoblastoid cell lines
constitutively produce Fas ligand and secrete MHCII+FasL+
killer exosomes
MatthewW. Klinker 1,2,Vincent Lizzio2,Tamra J. Reed 2, David A. Fox 1,2 and Steven K. Lundy 1,2*
1 Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, USA
2 Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
Edited by:
Sophie Brouard, Centre National de la
Recherche Scientifique, France
Reviewed by:
Marcella Franquesa, Erasmus
Medisch Centrum, Netherlands
Ignacio Anegon, Institut National de la
Santé et de la Recherche Médicale,
France
*Correspondence:
Steven K. Lundy, Division of
Rheumatology, Department of
Internal Medicine, University of
Michigan, Room 4043, BSRB, 109
Zina Pitcher Place, Ann Arbor, MI
48109-2200, USA
e-mail: sklundy@med.umich.edu
Immune suppression mediated by exosomes is an emerging concept with potentially
immense utility for immunotherapy in a variety of inflammatory contexts, including allo-
geneic transplantation. Exosomes containing the apoptosis-inducing molecule Fas ligand
(FasL) have demonstrated efficacy in inhibiting antigen-specific immune responses upon
adoptive transfer in animal models. We report here that a very high frequency of human B
cell-derived lymphoblastoid cell lines (LCL) constitutively produce MHCII+FasL+ exosomes
that can induce apoptosis in CD4+ T cells. All LCL tested for this study (>20 indepen-
dent cell lines) showed robust expression of FasL, but had no detectable FasL on the
cell surface. Given this intracellular sequestration, we hypothesized that FasL in LCL was
retained in the secretory lysosome and secreted via exosomes. Indeed, we found both
MHCII and FasL proteins present in LCL-derived exosomes, and using a bead-based exo-
some capture assay demonstrated the presence of MHCII+FasL+ exosomes among those
secreted by LCL. Using two independent experimental approaches, we demonstrated that
LCL-derived exosomes were capable of inducing antigen-specific apoptosis in autologous
CD4+ T cells. These results suggest that LCL-derived exosomes may present a realistic
source of immunosuppressive exosomes that could reduce or eliminate T cell-mediated
responses against donor-derived antigens in transplant recipients.
Keywords: lethal exosomes, transplant tolerance, Epstein–Barr virus, microvesicles,T cell apoptosis, regulatory B
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INTRODUCTION
Allograft rejection mediated by immune responses to donor-
derived antigens remains a significant concern following organ
transplantation (1). Alloreactive T cells are thought to be central
to the process of rejection,and most recipients of organ transplants
receive long-term treatment with immunosuppressive drugs that
globally suppress T cell responses. The broad immunosuppres-
sion mediated by these drugs can lead to increased susceptibility
to infection and reduced cancer surveillance in patients, and there-
fore a therapeutic means of targeting alloantigen-specific T cells
in transplant recipients would be a profound advancement over
current treatments.
Exosomes are extracellular vesicles approximately 50–90 nm
in diameter that are secreted by a variety of immune cells. In
antigen-presenting cells (APC), exosomes originate from the same
intracellular compartment where newly synthesized and recycled
MHCII molecules are loaded with peptides derived from endocy-
tosed proteins (2). While most reports suggest that the majority
of exosomes released by APC activate T cells, immunosuppressive
APC-derived exosomes have been described as well. Stimulation
of murine bone marrow-derived dendritic cells (BMDC) with IL-
10 resulted in the production of exosomes capable of suppressing
an immune response in vivo (3). Additionally, BMDC transfected
with a vector expressing the gene encoding the apoptosis-inducing
molecule Fas ligand (FasL) produced MHCII+FasL+ exosomes
that were able to suppress an immune response in vivo (4).
Importantly, the suppression mediated by the MHCII+FasL+ exo-
somes was antigen-specific and FasL-dependent. Naturally occur-
ring MHCII+FasL+ exosomes have been identified as well, and
these endogenously produced exosomes demonstrated antigen-
specific immune suppression upon transfer to recipient mice (5).
Immunosuppressive exosomes also were effective in prolonging
graft survival in a cardiac allograft model in rats (6). For the sup-
pression of human immune responses, exosomes may represent
a safer alternative to regulatory cells for immunotherapy because
the phenotype of exosomes is static, whereas regulatory cells can
potentially differentiate into effector cells after transfer (7). There-
fore, a cost-effective and reliable method for producing immuno-
suppressive MHCII+FasL+ exosomes is potentially of great value
for the development of exosome-based immunotherapies.
While FasL is most frequently studied in T cells or natural
killer (NK) cells, FasL expression by B cells has been reported in
numerous conditions (8). B cells expressing FasL were initially
observed following stimulation of murine B cells with mitogens
(9). Some forms of B cell-derived cancers in humans have been
reported to express FasL, including multiple myeloma, B cell
chronic lymphocytic leukemia, and large B cell lymphoma (10–
12). FasL-expressing B cells were induced by infection with the
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parasitic worm Schistosoma mansoni in mice, and their increased
frequency coincided with greater levels of apoptosis in CD4+ T
cells (13). There is also evidence that FasL-expressing B cells may
play a role in the regulation of autoimmunity and maintaining
self-tolerance. Activated B cells expressing FasL and TGFβ have
been reported to delay the onset of diabetes in non-obese diabetic
(NOD) mice, and the frequency of FasL+ B cells is reduced in mice
with severe autoimmune arthritis relative to those with mild or no
arthritis (14, 15). Mice with a B cell-specific loss of FasL sponta-
neously develop autoantibodies despite the fact that T cells in these
animals are FasL-sufficient, demonstrating that B cell expression of
FasL plays a role in maintaining immune homeostasis (16). Bone
marrow cells treated with the TLR-9 agonist CpG are enriched
for B cells that express high levels of FasL and protect NOD mice
from type 1 diabetes upon adoptive transfer (17). B cells from Fas-
deficient MRL/lpr mice also express high levels of FasL, and kill
Fas-susceptible target cells with an efficiency similar to that of NK
cells (18). In a male-to-female transplantation model, transfer of
B cells from wild-type males prior to skin grafting induced toler-
ance to H–Y antigen in female recipients, whereas FasL-deficient B
cells were unable to transfer tolerance (19). Taken together, these
studies demonstrate that FasL production by B cells is potentially
important for suppressing immune responses in many settings,
including tolerance of allografts.
In the current study, we report that a high frequency of lym-
phoblastoid cell lines (LCL) derived from human peripheral blood
B cells constitutively produce FasL protein. Importantly, all LCL-
tested secreted MHCII+FasL+ exosomes, and using two indepen-
dent experimental approaches, we demonstrated that LCL-derived
exosomes can induce targeted apoptosis in activated CD4+ T
cells. Therefore, we propose that exosomes produced by a donor-
derived LCL may represent a reliable source of alloantigen-specific
immunosuppressive exosomes that could potentially be used to
tolerize transplant recipients.
MATERIALS AND METHODS
PREPARATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS
All donors provided informed consent prior to their participa-
tion in this study. Blood was obtained by venipuncture and col-
lected into syringes containing sodium heparin. Following a 1:1
dilution with un-supplemented RPMI 1640, blood was gently lay-
ered onto Histopaque-1077 (Sigma-Aldrich) in 50 mL centrifuge
tubes. Buffy coats containing peripheral blood mononuclear cells
(PBMCs) were collected from tubes following centrifugation at
1,200× g for 30 min at 20°C.
CELL LINES
Lymphoblastoid cell lines were produced according to established
techniques for the transformation of B cells by Epstein–Barr virus
(EBV) using the non-replicating laboratory strain B95-8 (Amer-
ican Type Culture Collection) (20). Cell lines used were derived
from either healthy donors and generated in our laboratory, or
were from a collection of LCL derived from monozygotic twin
pairs discordant for rheumatoid arthritis (a kind gift from Dr.
Joseph Holoshitz, University of Michigan) (21). LCL were main-
tained in RPMI 1640 media supplemented with 20% FBS, 2%
l-glutamine, 1% penicillin/streptomycin, 1% non-essential amino
acids, and 1% sodium pyruvate. Most cell lines were kept in culture
continuously for longer than 2 months with no detectable changes
in growth, viability, or experimental results. Once or twice per
week, LCL cultures were split 1:3, and kept in a 37°C, 5% CO2
incubator.
EXOSOME ISOLATION AND PREPARATION FROM LCL CULTURE
SUPERNATANTS
Exosome-free FBS was produced by centrifuging FBS overnight
at 100,000× g to remove any bovine-derived exosomes. Culture
supernatants from LCL cultures were spun at 500× g for 10 min
to remove cells, followed by a spin at 10,000× g for at least 1 h to
remove large cellular debris and microparticles. Exosomes were
then obtained by centrifugation at 100,000× g for 1–4 h. The
resulting exosome pellets were diluted once with PBS prior to
another 100,000× g centrifugation, after which pellets were re-
suspended in a small volume of PBS. Protein concentration was
used as a proxy measure for the amount of exosomes in a given
re-suspension, and was determined by BCA assay. The presence of
microparticles with sizes that were consistent with exosomes was
confirmed by transmission electron microscopy (data not shown).
In some cases, supernatant from bulk cultures of LCL were con-
centrated using centrifuge tubes equipped with a 100-kDa filter
prior to exosome isolation by ultracentrifugation.
IMMUNOBLOTTING
Lymphoblastoid cell lines and LCL-derived exosomes were lysed
in SDS buffer prior to separation by SDS-PAGE and transfer
to a PVDF membrane. Membranes were blocked using man-
ufacturer recommended buffers specific to each antibody and
incubated with polyclonal rabbit anti-FasL IgG (Cell Signaling),
mouse anti-HLA-DR (Abcam, clone TAL 14.1), or polyclonal rab-
bit anti-β-Actin (Cell Signaling). Antibody binding was detected
with an anti-rabbit or anti-mouse IgG–HRP secondary antibody
(Cell Signaling) and ECL reagent (Thermo Scientific).
FLOW CYTOMETRY
PE-conjugated anti-FasL and isotype control antibody were
obtained from Biolegend (clone NOK-1). LCL were incubated
with anti-CD16/CD32 Fc Block (BD Biosciences) prior to stain-
ing and analyzed on a Beckman Coulter FC500 flow cytometer.
For intracellular staining, LCL were fixed for 20 min at room
temperature in 4% PFA, washed three times with PBS, and perme-
abilized with 0.5% saponin buffer prior to staining with anti-FasL.
For apoptosis staining, annexin-V-FITC (eBioscience) was used to
identify cells in early apoptosis and propidium iodide was used to
identify dead cells. Data were analyzed using Cytobank web-based
software (22) or FlowJo v7.6.5 (Tree Star, Inc.).
DENSITY GRADIENT CENTRIFUGATION
Serial dilutions of iodixanol (OptiPrep; Sigma-Aldrich) were pre-
pared with PBS, with densities ranging from 1.03 to 1.27 g/mL.
One milliliter of each density fraction was added sequentially to
an ultracentrifuge tube so as to maintain a discontinuous gradient.
A sample of LCL-derived exosomes in solution was placed on top
of the density gradient and centrifuged at 100,000× g for 1 h. Lay-
ers were then removed to separate tubes and diluted in PBS, and
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diluted fractions were centrifuged in individual tubes overnight
at 100,000× g. Pellets from each density fraction were lysed in an
equal amount of SDS buffer, and interrogated for FasL and MHCII
by immunoblot.
EXOSOME BEAD CAPTURE EXPERIMENTS
Polystyrene beads (~6.7µm diameter) coated with streptavidin
were obtained from Corpuscular Inc. or Spherotech Inc. Beads
were coated for 1 h at 20°C with biotinylated antibodies against
human HLA-DR (Biolegend, clone L243), or the appropriate iso-
type control antibody. After washing, antibody-coated beads were
incubated for 2–3 h with ultracentrifuge-purified exosomes at 4°C
with gentle agitation. Unbound exosomes were then washed away,
and bead-bound exosomes were stained for FasL and subsequently
analyzed on a Beckman Coulter FC500 flow cytometer.
EXOSOME-INDUCED APOPTOSIS ASSAYS (TT PEPTIDE)
Peripheral blood mononuclear cells were isolated from whole
blood and stimulated for 12 days with an immunodominant pep-
tide of tetanus toxoid (TT) (10µg/mL). This donor had received
a scheduled booster vaccination against tetanus within 2 months
of these experiments. CD4+ T cells were separated from PBMCs
cultures by negative selection by MACS (Miltenyi Biotec) and
cultured overnight with exosomes (156µg total protein/mL for
the experiment shown) derived from an autologous LCL in the
presence or absence of the stimulating peptide. The number of
exosomes used for each experiment was optimized based on the
yield from ultracentrifugation and was the same for all wells of
the experiment. Total exosome protein content measurement was
used to assess the inter-experimental variability and ranged from
100 to 250µg/mL in all experiments. The activity of FasL was
blocked in culture by the addition of 10µg/mL of anti-FasL anti-
body (BioLegend; clone NOK-1). Apoptosis was assessed in T
cells by annexin-V/propidium iodide staining among activated
(CD4+CD62Lneg) T cells.
EXOSOME-INDUCED APOPTOSIS ASSAYS (SEA)
CD4+ T cells were isolated from whole blood by RosetteSep
Human CD4+ T cell enrichment cocktail (Stem Cell Technolo-
gies) and stimulated for 6 days with Staphylococcal enterotoxin A
(10 ng/mL; Sigma-Aldrich) in the presence or absence of exosomes
(127µg/mL) purified from an autologous LCL. T cells were then
harvested and apoptosis was assessed by annexin-V/propidium
iodide staining among total CD4+ T cells.
RESULTS
HIGH FREQUENCY OF LCL CONSTITUTIVELY PRODUCES
INTRACELLULAR FasL PROTEIN
To study the regulation and trafficking of FasL in B cells, we
obtained several B cell-derived cell lines to screen for FasL expres-
sion. Among the cell lines tested were several LCL generated by
transformation of human peripheral blood B cells with the atten-
uated B95-8 clone of EBV (23). By immunoblotting for FasL, we
found that all LCL tested (>20 independent lines) displayed robust
and constitutive expression of FasL protein (Figure 1A). Expres-
sion of FasL in the myeloid leukemia cell line, K562, and the T
cell leukemia line, Jurkat, was not detected. Other B cell-derived
FIGURE 1 | A high frequency of LCL constitutively produce intracellular
FasL protein. (A) Equivalent numbers of LCL and control cell lines were
lysed and probed for expression of FasL protein by immunoblot. (B) LCL
were fixed and stained for surface FasL, or permeabilized with saponin
buffer for intracellular FasL staining by flow cytometry. An isotype control
antibody was used to control for non-specific binding on the cell surface
and following cell permeabilization. Results are representative of at least
three LCL tested.
cell lines such as human B cell lymphomas were only sporadically
FasL+ (data not shown). We therefore conclude that a high fre-
quency of cell lines made by transformation of human B cells with
EBV constitutively produce FasL protein.
We next sought to determine the cellular localization of FasL in
LCL by flow cytometry. To this end, we stained the surface of LCL
cells with anti-FasL antibody or an appropriate isotype control
antibody. Somewhat surprisingly, we found little or no detectable
FasL on the surface of all LCL tested (Figure 1B). After fixation
and permeabilization, however, we were able to detect intracellular
FasL in all LCL tested (Figure 1B). It therefore appears that while
LCL constitutively produce FasL protein, very little FasL is present
on the cell surface under normal culture conditions.
LCL SECRETE EXOSOMES CONTAINING FasL AND MHC CLASS II
Lymphoblastoid cell lines are known to spontaneously secrete
exosomes, but there are no reports of LCL-derived exosomes con-
taining FasL (2). Additionally, the secretory lysosome is the default
destination for FasL in cells, which possess this compartment (24).
We therefore hypothesized that as LCL express robust amounts of
FasL, this FasL is likely to be sorted to the secretory lysosome
and secreted on exosomes. To test this hypothesis, we collected
supernatants from several independent LCL and isolated exosomes
from these supernatants using ultracentrifugation. Briefly, cells
and large debris were removed from supernatants by centrifuga-
tion at 500× g and 10,000× g, respectively. To pellet exosomes,
the cleared supernatants were spun at 100,000× g for 1–4 h. The
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FIGURE 2 | LCL secrete exosomes containing FasL and MHC class II.
(A) Cell lysates and spontaneously secreted exosomes were collected from
four LCL (lines E, P, 2, and 4) and probed for the presence of FasL and
HLA-DR by immunoblot. (B) Exosomes from a representative LCL were
floated onto a discontinuous density gradient of iodixanol solution and spun
for 1 h at 100,000×g. Individual layers were removed and diluted with PBS,
followed by an overnight centrifugation at 100,000×g. The resulting pellets
were lysed with SDS buffer and probed for FasL by immunoblot.
resulting exosome pellets were lysed with SDS buffer and probed
for expression of FasL and HLA-DR by immunoblot. FasL was
detectable in the exosome fraction from all LCL tested (Figure 2A).
We also confirmed that MHCII molecules were present in LCL-
derived exosomes, as we found abundant HLA-DR in the exosome
pellets as well (Figure 2A).
The pellet obtained by centrifuging supernatants at 100,000× g
can potentially be contaminated with large soluble complexes or
other types of cell debris. It has been reported that exosomes have
a characteristic density distinct from other membrane fragments
or microparticles (2). We therefore centrifuged re-suspended LCL-
derived exosomes through a discontinuous density gradient made
by serial dilution of iodixanol in PBS. After spinning for 1 h at
100,000× g, each layer was harvested and diluted in PBS, and cen-
trifuged again at 100,000× g overnight. The resulting pellets were
then lysed in SDS buffer and probed for the presence of FasL by
immunoblot as in Figure 1A. FasL protein was detected only in
the fraction with a density of 1.16 g/mL (Figure 2B), a density
indicative of exosomes (2). Taken together, these data demon-
strate that exosomes containing FasL are constitutively secreted
by LCL.
DOUBLE-POSITIVE FasL+MHCII+ EXOSOMES ARE PRESENT AMONG
LCL-DERIVED EXOSOMES
Our previous experiments demonstrated that both FasL and
MHCII protein were present in exosomes secreted by LCL. While
both proteins are present on exosomes, it is not clear from the
previous data whether individual exosomes possess both FasL
and MHCII (FasL+MHCII+), or whether FasL and MHCII are
present on distinct subsets of exosomes. Exosomes are too small
to be accurately detected by standard flow cytometry, and so
must be linked in aggregate to larger beads for flow cytometric
analysis. We therefore developed an assay to capture exosomes on
an antibody-coated bead and stain the captured exosomes with
fluorescently conjugated antibodies (Figure 3). Polystyrene beads
coated with streptavidin were incubated with a biotinylated anti-
body and washed several times. Antibody-coated beads were then
incubated with exosomes, and after washing away excess exosomes,
those bound to the beads were stained with anti-FasL antibody
(Figure 3).
To test for the co-localization of MHCII and FasL into the
same exosomes, we harvested exosomes from unstimulated and
PMA/ionomycin-stimulated LCL culture supernatants and con-
centrated them by centrifugation. Exosomes were then incu-
bated with beads coated with anti-MHCII antibody, and stained
with anti-FasL or isotype control antibodies. As can be seen in
Figure 4A, exosomes bound to anti-MHCII-coated beads stained
positive for the presence of FasL, demonstrating that FasL and
MHCII are found on the same LCL-derived exosomes. Stimula-
tion with PMA/ionomycin increased the amount of FasL detected
on MHCII+ exosomes in both LCL tested (Figure 4A). Cells from
these experiments were also lysed and probed for FasL, and both
cell lines had increased cellular FasL protein levels in response to
PMA/ionomycin stimulation (Figure 4B). Therefore, LCL secrete
MHCII+FasL+ exosomes, and both the production of FasL pro-
tein and the release of MHCII+FasL+ exosomes can be increased
by stimulation with PMA/ionomycin.
LCL-DERIVED EXOSOMES CAN INDUCE APOPTOSIS IN AUTOLOGOUS
CD4+ T CELLS
Since LCL-derived exosomes contained a measurable amount of
MHCII+FasL+ exosomes, we hypothesized that activated CD4+ T
cells would be susceptible to exosome-induced apoptosis. To test
this hypothesis,we obtained PBMCs from a healthy donor who had
been recently immunized against tetanus and from whom we had
previously made an LCL and could collect autologous exosomes.
T cells specific for a nominal antigen are rare among peripheral
CD4+ T cells, and therefore detecting the capacity of LCL-derived
exosomes to induce peptide antigen-specific apoptosis requires
prior activation to enrich for peptide-specific T cells. PBMCs from
this donor were cultured with the immunodominant peptide of TT
to enrich the CD4+ T cell pool for cells specific to this antigen. After
12 days in culture, CD4+ T cells were isolated by negative selec-
tion. To demonstrate the antigen-specificity of exosome-mediated
T cell apoptosis, the same TT peptide was introduced in excess to
a portion of LCL-derived exosomes to displace peptides already
present on the exosome MHC class II molecule. CD4+ T cells
were then incubated overnight with autologous LCL-derived exo-
somes in the presence or absence of the TT peptide. Apoptosis was
assessed by annexin-V/propidium iodide staining among activated
T cells (CD4+CD62Lneg). LCL-derived exosomes in the presence
of TT peptide induced significant levels of apoptosis in CD4+
CD62Lneg T cells (Figure 5). While exosomes that were not loaded
with TT peptide also induced apoptosis above baseline, this differ-
ence did not reach statistical significance (Figure 5). The addition
of a neutralizing anti-FasL antibody to culture with exosomes and
TT peptide appeared to inhibit exosome-induced apoptosis, but
this difference also did not reach statistical significance (Figure 5).
Taken together, these data suggest that LCL-derived exosomes can
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FIGURE 3 | Diagram of exosome-bead capture experiments.
Exosomes are too small to be accurately detected by standard flow
cytometry, and so must be linked in aggregate to larger beads for flow
cytometric analysis. Polystyrene beads coated with streptavidin were
incubated with biotin-conjugated anti-HLA-DR or an isotype control
antibody. Beads were then washed and incubated with gentle agitation
for several hours with LCL-derived exosomes. Beads were washed and
stained with PE-conjugated anti-FasL or an appropriate isotype antibody.
Positive staining for FasL indicates the presence of MHCII+FasL+
exosomes.
induce apoptosis in activated T cells that is antigen-dependent and
may be at least partially mediated by FasL.
To assess the ability of LCL-derived exosomes to induce apop-
tosis of T cells that had not previously been exposed to antigen, we
employed the super-antigen, staphylococcal enterotoxin A (SEA),
to facilitate interactions between MHC class II and the T cell recep-
tor. LCL-derived exosomes were isolated from unstimulated LCL
culture supernatant as described above and cultured with fresh
CD4+ T cells in the presence or absence of SEA. After 6 days
in culture, we assessed apoptosis in CD4+ T cells by annexin-
V/propidium iodide staining. In the absence of SEA, LCL-derived
exosomes produced a modest increase in apoptosis in CD4+ T cells
(Figure 6). In contrast, in the presence of SEA, exosomes induced
significant levels of apoptosis in CD4+ T cells (Figure 6). Similar
results were obtained using an LCL and CD4+ T cells from a second
independent donor (data not shown). Taken together, these results
suggest that LCL-derived exosomes can mediate antigen-specific
killing of CD4+ T cells.
DISCUSSION
Exosome-mediated immunotherapy for the treatment of inflam-
matory disorders is an intriguing concept because MHCII+FasL+
exosomes have demonstrated permanent and precisely focused
suppression of antigen-specific immune responses in mouse mod-
els (4, 5). For the treatment of human inflammatory conditions,
exosomes may represent a safer alternative to regulatory cells for
immunotherapy because the phenotype of exosomes is expected
to be static, whereas regulatory cells can potentially differentiate
into effector cells after transfer (7). Although this technique has
promise, a reliable method for producing donor-derived immuno-
suppressive exosomes is required before this therapeutic strategy
can be developed as a strategy to induce and maintain tolerance
after transplantation. We show here that transformation of human
B cells with EBV results in robust expression of FasL, and that
all LCL tested in this study also produced MHCII+FasL+ exo-
somes. Generating LCL from peripheral blood B cells is widely
practiced and a relatively simple process, requiring only minimal
laboratory labor and reagents. The resulting transformed B cells
can be grown to high concentrations and stored over long peri-
ods of time. Therefore, LCL represent a potentially reliable source
of immunosuppressive exosomes from any donor that could be
therapeutically useful in humans.
B cells expressing FasL are relatively infrequent under most
conditions, and we therefore hypothesized at the outset of this
project that FasL expression among human B cell-derived tumor
lines would be rare as well. While FasL expression was indeed
infrequent among primary B cells and cell lines derived from
other types of B cell cancers, we found that FasL protein was
present in cell lysates from all LCL tested in this study. This result
was somewhat surprising as LCL are reportedly susceptible to
FasL-induced apoptosis, and LCL have been used extensively as
APC for activating T cells (25–28). These conflicting results can
be explained in part by the fact that unlike endogenous FasL+
B cells in mice, FasL protein is undetectable on the surface of
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FIGURE 4 | LCL secrete MHCII+FasL+ exosomes. (A) Two LCL
(designated “LCL-E” and “LCL-P”) were placed into fresh exosome-free
media in the presence or absence of PMA/ionomycin. After 5 h (top panels)
or 24 h (bottom panels), exosomes were isolated from culture supernatants
as described in the section “Materials and Methods.” Purified exosomes
were then incubated with anti-HLA-DR-coated beads as described in
Figure 3. Beads were washed and stained with either anti-FasL or an
isotype control antibody. Beads were coated with an appropriate isotype
control antibody as the capture antibody did not display any FasL staining
(data not shown). (B) Cells from above experiment were harvested, lysed,
and probed for FasL and MHCII (HLA-DR) by immunoblot.
LCL. Therefore, although LCL produce FasL, this intracellular
sequestration makes it unavailable for inducing apoptosis in tar-
get cells unless transported to the cell surface or released. In the
present study, we demonstrate that PMA/ionomycin stimulation
triggers increased production of FasL protein by LCL, as well as
the release of FasL+MHCII+ exosomes. These data suggest that
antigen receptor- and calcium-dependent signaling pathways are
involved in the regulation of FasL+ exosome transport. Other
studies have demonstrated that ligation of ICAM-1, B7-H1, or B7-
H4 on cultured LCL leads to activation of reactive oxygen species,
which in turn cause the translocation of FasL to the cell surface
and induction of LCL apoptosis, however the release of FasL+
exosomes was not measured (29–31).
The high frequency of FasL expression and exosome release
among LCL suggests that FasL may be an important component
of natural EBV infection. LCL are generated experimentally by
infection with the B95-8 strain of EBV, which is a replication
incompetent form of the native γ-1 herpes virus that has onco-
genic potential in humans (32). The natural virus persists in most
infected individuals in latently infected circulating memory B cells
(33, 34). Greater than 90% of adults have been infected with
EBV, and although clinical manifestations of infection are gen-
erally rare, the transforming properties of the virus can lead to
B cell-derived malignancies such as Burkitt’s and Hodgkin lym-
phomas (35, 36). LCL generated by infection with EBV maintain a
latent viral growth program, expressing at least eight proteins from
the viral genome (35). Among these proteins is latent membrane
protein 1 (LMP1), a functional mimic of CD40 (37). Signaling
of LMP1 differs from that mediated by CD40, as LMP1 signal-
ing is constitutive rather than ligand-dependent. Therefore, LCL
are essentially in a state of constant CD40 stimulation. We previ-
ously observed that mouse B cells stimulated in vitro with CD40L
and IL-5 express higher levels of FasL (38), and therefore the
CD40-mimicry of LMP1 might potentially explain the constitu-
tive production of FasL in LCL. Additionally, stimulation with
CD40L has been reported to induce FasL expression in other types
of cells (39–41).
The expression of FasL by LCL and their production of
FasL+/MHCII+ exosomes may have important implications in
clinical management of EBV infections. While most people are first
exposed to EBV in infancy, those infected later in life can develop
acute infectious mononucleosis (AIM) (42). At the height of acute
infection, T cells are susceptible to Fas-mediated apoptosis, and
in vitro infection of PBMCs with EBV leads to elevated levels of
FasL on the surface of B cells (43). Inducing surface expression
of FasL in B cells may therefore be a means of immune evasion
employed by EBV during the lytic cycle (44). Importantly, FasL
localization appears to differ between the lytic and latent cycles,
as FasL in LCL is intracellular whereas FasL can be found on the
surface of B cells during acute infection (43). As the virus transi-
tions into a latent state and settles into homeostasis with the host
immune system, infected B cells may maintain FasL production
but cease transporting it to the cell surface. This may represent
a natural mechanism by which LCL can persist without causing
significant tissue damage while maintaining the ability to ward off
elimination by virus-specific T lymphocytes.
We demonstrate here that LCL constitutively produce
MHCII+FasL+ exosomes with apoptosis-inducing activity against
CD4+ T cells. Although FasL can be detected in LCL-
derived exosomes under normal conditions, stimulation with
PMA/ionomycin increased both the amount of MHCII+FasL+
exosomes secreted and FasL production in LCL. However, while
FasL is abundant in LCL cell lysates, it is relatively difficult to detect
in exosomes, even after stimulation. In contrast, the expression of
MHC class II was very abundant in exosomes in comparison to
FasL. Based on these findings, we hypothesize that LCL may pro-
duce a mixture of MHC class II+ exosomes that are either FasL+
or FasL−. It has proven difficult to separate these potential LCL-
derived exosome subsets using current techniques (45, 46). Some
limitations were created because anti-human or mouse FasL anti-
bodies have been unable to capture exosomes (data not shown),
and the beads used for exosome capture have multiple binding
sites that can potentially capture several different exosomes simul-
taneously. These are important limitations to the current study
because there is likely to be a balance of stimulation with and
without concomitant T cell apoptosis in our experimental model
system. The balance of these two forces may explain some seem-
ingly contradictory results that have been published regarding
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FIGURE 5 | Antigen-specific killing withTT peptide. Peripheral blood
mononuclear cells were harvested from a repeat donor from whom we had
previously generated an LCL. This donor had received a scheduled
vaccination against tetanus <1 month prior to the experiment shown.
PBMCs were cultured in the presence of an immunodominant peptide of the
tetanus toxoid for 12 days. CD4+ T cells were then isolated by negative
selection and cultured overnight with or without autologous LCL-derived
exosomes (156µg/mL) and in the presence or absence of the tetanus toxoid
peptide. Neutralizing anti-human FasL antibodies (10µg/mL) were added to
some wells to block interactions between exosome FasL and Fas on the
target cells. Apoptosis in activated CD4+CD62Lneg T cells was assessed by
annexin-V/propidium iodide staining. Two additional experiments with the
same donor cells showed the similar trends but were less robust,
presumably due to the loss of tetanus-specificT cells in vivo as the time after
vaccination increased. (A) Representative contour plots of annexin-V and
propidium iodide staining among CD4+CD62Llow-gated T cells. (B) Frequency
of annexin-V+ cells (mean±SEM of triplicate samples) among
CD4+CD62Llow T cells. *p<0.05.
the immune modulatory properties of adoptively transferred exo-
somes in vivo (6, 47). Notably, most studies showing stimulation
of immune responses by adoptive transfer of exosomes in mice
have not included an assessment of exosome FasL expression or
apoptosis. Until better methods of FasL+ exosome capture or sep-
aration can be developed, it will remain difficult to analyze their
immunotherapeutic potential in complex animal models such as
allotransplantation.
Despite the likelihood of contamination by FasL− exosomes,
the exosomes were able to induce apoptosis in approximately 25%
of the TH cells in the cultures when super-antigen or an antigenic
peptide with which the TH cells had been previously activated
were present. The partial blockade of killing when anti-human
FasL antibody was added to the culture indicates that there may
be additional mechanisms of cell death occurring. This is not sur-
prising given the heterogeneity of the exosome preparation and
the potential for other death ligands such as TRAIL or TNF to be
expressed on exosomes (40, 48). It will be interesting to determine
how parameters such as dose, timing, and efficiency of eliminat-
ing allo-specific T cells in vitro and in vivo will be affected by
improvements in purification of FasL+ exosomes.
There remain many important considerations to address before
FasL+ exosomes can be used in clinical trials. A top priority will
be to develop the methods of selectively and efficiently separating
FasL+MHCII+ exosomes from FasL− exosomes. Our data show
that FasL+ exosomes were highly enriched at a specific den-
sity of 1.16 g/mL. This fraction also contained MHCII molecules
(data not shown), however, several other density fractions also
had MHCII at similar levels without FasL, suggesting that FasL+
exosomes are only a small component of exosomes released by
LCL. Density gradient centrifugation may be a useful method for
enriching FasL+ exosomes, but it may prove more efficient to iso-
late these exosomes by immunoaffinity capture techniques (49).
Once reliable methods have been developed to purify FasL+ exo-
somes, it should be feasible to demonstrate their antigen-specific
immune suppressive properties using in vitro mixed lymphocyte
reactions and in vivo adoptive transfer models in mice.
Another important caveat to consider is the effect of such a ther-
apy on the ability of the recipient to control latent EBV infections,
as >90% of patients may harbor endogenous virus. While CD8+
T cells among PBMCs are relatively resistant to FasL-mediated
apoptosis, it may still be desirable to reduce MHC class I lev-
els in LCL-derived exosomes to prevent them from interacting
with CD8+ T cells after transfer (50). This could be accomplished
by introducing engineered gene-specific nucleases that can target
genes important for MHC class I expression in the recombinant
EBV genome, such as transporter associated with antigen process-
ing (TAP) or β2 microglobulin (51, 52). Such a strategy would
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FIGURE 6 | LCL-derived exosomes can induce apoptosis in autologous
CD4+ T cells. CD4+ T cells were harvested from a repeat donor from whom
we had previously generated an LCL. CD4+ T cells were incubated with
exosomes (127µg/mL) in the presence or absence of the super-antigen,
staphylococcal enterotoxin A (SEA). After 6 days in culture, PBMCs were
harvested and apoptosis was assessed in CD4+ T cells by
annexin-V/propidium iodide staining. Data are representative of three
independent experiments using exosomes from this donor. Similar results
were obtained using exosomes from a different LCL donor (data not
shown). *p<0.05, **p<0.01, ***p<0.001.
expectedly reduce the amount of MHC class I on exosomes, and
therefore reduce the likelihood that LCL-derived exosomes would
deplete EBV-specific CD8+ T cells in LCL-exosome recipients.
CD4+ T cell immunity also appears to be crucial for control-
ling the latent EBV infection (53). To overcome the potential loss
of virus-specific CD4+ T cells, it may be necessary to vaccinate
recipients of LCL-derived FasL+ exosomes post-transplantation
to reestablish immunity against EBV.
Despite the concerns listed above, there are many positive
aspects to using EBV-transformed B cells as a source of tolero-
genic exosomes. Generating LCL with B95-8 EBV has proven to be
a simple, reliable, and safe method that has already been used to
produce thousands of lines that could serve as a source of FasL+
exosomes. Huge repositories of LCL exist containing many lines
that have been genotyped for MHC class I and class II expres-
sion and the high frequency of FasL expression by LCL also makes
it feasible to generate de novo LCL from people on organ donor
registries with exact MHC representation. EBV transformation
results in a homogeneous culture of immortalized B cells that
grow rapidly, can be maintained at high cell densities, and does not
require cell sorting to remove contaminating cell populations. Exo-
somes are reportedly stable in phenotype and can be stored over
long periods of time without significant loss of function (54). The
genome of EBV is maintained in proliferating LCL as a large epi-
some (~167 kb), and techniques for engineering recombinant EBV
are well-established (55, 56). The large size of the viral genome will
allow for the addition of transgenes to the virus, such as a segment
containing the FasL gene under a strong, ubiquitous promoter to
ensure robust production of FasL. Additionally, recombinant EBV
can be produced containing the coding sequence for tissue-specific
alloantigens fused to a lysosomal sorting sequence. Proteins con-
taining this sequence are actively sorted to the secretory lysosome
where they are processed and presented on MHCII molecules (57).
Thus, MHCII+FasL+ exosomes produced by such a LCL could
be engineered to present various epitopes of the alloantigen. The
resulting exosomes could be harvested under sterile conditions by
centrifugation, affinity, or filtration, and either frozen for future
use or administered directly to the patient.
The utility of LCL-derived FasL+ exosomes to tolerize allo-
graft recipients remains to be determined. Other potential uses of
these immune suppressive exosomes could include treatments for
T cell-mediated allergies and autoimmune diseases, since the goal
of eliminating antigen-specific T cells is similar in these condi-
tions. Alternatively, the development of effective tumor vaccines
using exosomes, which is currently being intensely studied, may
be dependent on the removal or suppression of FasL+ exosomes
from the preparation. An important consideration is that exo-
somes have the ability to travel relatively far away from the cells that
produced them, and yet perform many of the same functions that
have been previously attributed to direct cell–cell contact. Much
controversy has existed over the functions of soluble forms of FasL,
yet until recently there was no distinction made between truly sol-
uble FasL and vesicular FasL. The recent developments in the field
of exosome research should cause a reassessment of what we think
is known about cellular interactions in the immune system and
consequently to our approaches toward immunotherapy.
REFERENCES
1. Liu Z, Fan H, Jiang S. CD4(+) T-cell subsets in transplantation. Immunol Rev
(2013) 252(1):183–91. doi:10.1111/imr.12038
2. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief
CJ, et al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med (1996)
183(3):1161–72. doi:10.1084/jem.183.3.1161
3. Kim SH, Lechman ER, Bianco N, Menon R, Keravala A, Nash J, et al. Exo-
somes derived from IL-10-treated dendritic cells can suppress inflammation
and collagen-induced arthritis. J Immunol (2005) 174(10):6440–8.
4. Kim SH, Bianco N, Menon R, Lechman ER, Shufesky WJ, Morelli AE, et al.
Exosomes derived from genetically modified DC expressing FasL are anti-
inflammatory and immunosuppressive. Mol Ther (2006) 13(2):289–300. doi:
10.1016/j.ymthe.2005.09.015
5. Kim SH, Bianco NR, Shufesky WJ, Morelli AE, Robbins PD. MHC class II+
exosomes in plasma suppress inflammation in an antigen-specific and Fas
ligand/Fas-dependent manner. J Immunol (2007) 179(4):2235–41.
6. Pêche H, Renaudin K, Beriou G, Merieau E, Amigorena S, Cuturi MC. Induction
of tolerance by exosomes and short-term immunosuppression in a fully MHC-
mismatched rat cardiac allograft model. Am J Transplant (2006) 6(7):1541–50.
doi:10.1111/j.1600-6143.2006.01344.x
7. Ohkura N, Kitagawa Y, Sakaguchi S. Development and maintenance of regula-
tory T cells. Immunity (2013) 38(3):414–23. doi:10.1016/j.immuni.2013.03.002
8. Lundy SK. Killer B lymphocytes: the evidence and the potential. Inflamm Res
(2009) 58(7):345–57. doi:10.1007/s00011-009-0014-x
9. Hahne M, Renno T, Schroeter M, Irmler M, French L, Bornard T, et al. Acti-
vated B cells express functional Fas ligand. Eur J Immunol (1996) 26(3):721–4.
doi:10.1002/eji.1830260332
10. Villunger A, Egle A, Marschitz I, Kos M, Böck G, Ludwig H, et al. Constitutive
expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a poten-
tial mechanism of tumor-induced suppression of immune surveillance. Blood
(1997) 90(1):12–20.
11. Tinhofer I, Marschitz I, Kos M, Henn T, Egle A, Villunger A, et al. Differential
sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-
1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. Blood (1998)
91(11):4273–81.
Frontiers in Immunology | Alloimmunity and Transplantation April 2014 | Volume 5 | Article 144 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Klinker et al. B-LCL-derived FasL+ killer exosomes
12. Kojima Y, Tsurumi H, Goto N, Shimizu M, Kasahara S, Yamada T, et al. Fas and
Fas ligand expression on germinal center type-diffuse large B-cell lymphoma
is associated with the clinical outcome. Eur J Haematol (2006) 76(6):465–72.
doi:10.1111/j.1600-0609.2006.00631.x
13. Lundy SK, Lerman SP, Boros DL. Soluble egg antigen-stimulated T helper lym-
phocyte apoptosis and evidence for cell death mediated by FasL(+) T and
B cells during murine Schistosoma mansoni infection. Infect Immun (2001)
69(1):271–80. doi:10.1128/IAI.69.1.271-280.2001
14. Tian J, Zekzer D, Hanssen L, Lu Y, Olcott A, Kaufman DL. Lipopolysaccharide-
activated B cells down-regulate Th1 immunity and prevent autoimmune dia-
betes in nonobese diabetic mice. J Immunol (2001) 167(2):1081–9.
15. Lundy SK, Fox DA. Reduced Fas ligand-expressing splenic CD5+ B lympho-
cytes in severe collagen-induced arthritis. Arthritis Res Ther (2009) 11(4):R128.
doi:10.1186/ar2795
16. Mabrouk I, Buart S, Hasmim M, Michiels C, Connault E, Opolon P, et al. Pre-
vention of autoimmunity and control of recall response to exogenous antigen by
Fas death receptor ligand expression on T cells. Immunity (2008) 29(6):922–33.
doi:10.1016/j.immuni.2008.10.007
17. Montandon R, Korniotis S, Layseca-Espinosa E, Gras C, Mégret J, Ezine S,
et al. Innate pro-B-cell progenitors protect against type 1 diabetes by reg-
ulating autoimmune effector T cells. Proc Natl Acad Sci U S A (2013)
110(24):E2199–208. doi:10.1073/pnas.1222446110
18. Bonardelle D, Benihoud K, Kiger N, Bobé P. B lymphocytes mediate Fas-
dependent cytotoxicity in MRL/lpr mice. J Leukoc Biol (2005) 78(5):1052–9.
doi:10.1189/jlb.0904536
19. Minagawa R, Okano S, Tomita Y, Kishihara K, Yamada H, Nomoto K, et al.
The critical role of Fas-Fas ligand interaction in donor-specific transfusion-
induced tolerance to H-Y antigen. Transplantation (2004) 78(6):799–806.
doi:10.1097/01.TP.0000129799.96439.6F
20. Tosato G, Cohen JI. Generation of Epstein-BarrVirus (EBV)-immortalized B cell
lines. Curr Protoc Immunol (2007) Chapter 7:Unit722. doi:10.1002/0471142735.
im0722s76
21. Haas CS, Creighton CJ, Pi X, Maine I, Koch AE, Haines GK, et al. Identification of
genes modulated in rheumatoid arthritis using complementary DNA microar-
ray analysis of lymphoblastoid B cell lines from disease-discordant monozygotic
twins. Arthritis Rheum (2006) 54(7):2047–60. doi:10.1002/art.21953
22. Kotecha N, Krutzik PO, Irish JM. Web-based analysis and publication of
flow cytometry experiments. Curr Protoc Cytom (2010) Chapter 10:Unit1017.
doi:10.1002/0471142956.cy1017s53
23. Miller G, Robinson J, Heston L, Lipman M. Differences between labora-
tory strains of Epstein-Barr virus based on immortalization, abortive infec-
tion, and interference. Proc Natl Acad Sci U S A (1974) 71(10):4006–10.
doi:10.1073/pnas.71.10.4006
24. Blott EJ, Bossi G, Clark R, Zvelebil M, Griffiths GM. Fas ligand is targeted to
secretory lysosomes via a proline-rich domain in its cytoplasmic tail. J Cell Sci
(2001) 114(Pt 13):2405–16.
25. de Campos-Lima PO,Torsteinsdóttir S,Cuomo L,Klein G,Sulitzeanu D,Masucci
MG. Antigen processing and presentation by EBV-carrying cell lines: cell-
phenotype dependence and influence of the EBV-encoded LMP1. Int J Cancer
(1993) 53(5):856–62. doi:10.1002/ijc.2910530525
26. Rowe M, Khanna R, Jacob CA, Argaet V, Kelly A, Powis S, et al. Restoration
of endogenous antigen processing in Burkitt’s lymphoma cells by Epstein-
Barr virus latent membrane protein-1: coordinate up-regulation of pep-
tide transporters and HLA-class I antigen expression. Eur J Immunol (1995)
25(5):1374–84. doi:10.1002/eji.1830250536
27. Tatsuta T, Cheng J, Mountz JD. Intracellular IL-1beta is an inhibitor of Fas-
mediated apoptosis. J Immunol (1996) 157(9):3949–57.
28. Wilson AD, Redchenko I, Williams NA, Morgan AJ. CD4+ T cells inhibit growth
of Epstein-Barr virus-transformed B cells through CD95-CD95 ligand-mediated
apoptosis. Int Immunol (1998) 10(8):1149–57. doi:10.1093/intimm/10.8.1149
29. Kim YS, Park GB, Song HK, Hur I, Lee HK, Kang JS, et al. Cross-linking of
CD54 on Burkitt lymphoma cell line Raji and Ramos induces FasL expression
by reactive oxygen species and apoptosis of adjacent cells in Fas/FasL interaction.
J Immunother (2007) 30(7):727–39. doi:10.1097/CJI.0b013e31814a69fa
30. Kim YS, Park GB, Lee HK, Song H, Choi IH, Lee WJ, et al. Cross-linking of
B7-H1 on EBV-transformed B cells induces apoptosis through reactive oxygen
species production, JNK signaling activation, and FasL expression. J Immunol
(2008) 181(9):6158–69.
31. Song H, Park G, Kim YS, Hur I, Kim H, Ryu JW, et al. B7-H4 reverse signal-
ing induces the apoptosis of EBV-transformed B cells through Fas ligand up-
regulation. Cancer Lett (2008) 266(2):227–37. doi:10.1016/j.canlet.2008.02.067
32. Kuppers R. B cells under influence: transformation of B cells by Epstein-Barr
virus. Nat Rev Immunol (2003) 3(10):801–12. doi:10.1038/nri1201
33. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. EBV persistence in mem-
ory B cells in vivo. Immunity (1998) 9(3):395–404. doi:10.1016/S1074-7613(00)
80622-6
34. Joseph AM, Babcock GJ, Thorley-Lawson DA. EBV persistence involves strict
selection of latently infected B cells. J Immunol (2000) 165(6):2975–81.
35. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat
Rev Immunol (2001) 1(1):75–82. doi:10.1038/35095584
36. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infec-
tion in humans: lessons from Epstein-Barr virus. Annu Rev Immunol (2007)
25:587–617. doi:10.1146/annurev.immunol.25.022106.141553
37. Uchida J, Yasui T, Takaoka-Shichijo Y, Muraoka M, Kulwichit W, Raab-
Traub N, et al. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B
lymphocyte responses. Science (1999) 286(5438):300–3. doi:10.1126/science.
286.5438.300
38. Klinker MW, Reed TJ, Fox DA, Lundy SK. Interleukin-5 supports the expan-
sion of Fas ligand-expressing killer B cells that induce antigen-specific apoptosis
of CD4(+) T cells and secrete interleukin-10. PLoS One (2013) 8(8):e70131.
doi:10.1371/journal.pone.0070131
39. Afford SC, Randhawa S, Eliopoulos AG, Hubscher SG, Young LS, Adams
DH. CD40 activation induces apoptosis in cultured human hepatocytes via
induction of cell surface Fas ligand expression and amplifies Fas-mediated
hepatocyte death during allograft rejection. J Exp Med (1999) 189(2):441–6.
doi:10.1084/jem.189.2.441
40. Eliopoulos AG, Davies C, Knox PG, Gallagher NJ, Afford SC, Adams DH,
et al. CD40 induces apoptosis in carcinoma cells through activation of cyto-
toxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol (2000)
20(15):5503–15. doi:10.1128/MCB.20.15.5503-5515.2000
41. Shibaki A, Katz SI. Activation through CD40 ligation induces functional
Fas ligand expression by Langerhans cells. Eur J Immunol (2001) 31(10):
3006–15. doi:10.1002/1521-4141(2001010)31:10<3006::AID-IMMU3006>3.0.
CO;2-L
42. Crawford DH, Macsween KF, Higgins CD, Thomas R, McAulay K, Williams H,
et al. A cohort study among university students: identification of risk factors for
Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis
(2006) 43(3):276–82. doi:10.1086/505400
43. Tanner JE, Alfieri C. Epstein-Barr virus induces Fas (CD95) in T cells and Fas
ligand in B cells leading to T-cell apoptosis. Blood (1999) 94(10):3439–47.
44. Ohshima K, Suzumiya J, Sugihara M, Nagafuchi S, Ohga S, Kikuchi M. CD95
(Fas) ligand expression of Epstein-Barr virus (EBV)-infected lymphocytes: a
possible mechanism of immune evasion in chronic active EBV infection. Pathol
Int (1999) 49(1):9–13. doi:10.1046/j.1440-1827.1999.00816.x
45. Johansson SM, Admyre C, Scheynius A, Gabrielsson S. Different types of in vitro
generated human monocyte-derived dendritic cells release exosomes with dis-
tinct phenotypes. Immunology (2008) 123(4):491–9. doi:10.1111/j.1365-2567.
2007.02714.x
46. Bobrie A, Colombo M, Krumeich S, Raposo G, Théry C. Diverse subpopula-
tions of vesicles secreted by different intracellular mechanisms are present in
exosome preparations obtained by differential ultracentrifugation. J Extracell
Vesicles (2012) 1:18397. doi:10.3402/jev.v1i0.18397
47. Admyre C, Bohle B, Johansson SM, Focke-Tejkl M, Valenta R, Scheynius A, et al.
B cell-derived exosomes can present allergen peptides and activate allergen-
specific T cells to proliferate and produce TH2-like cytokines. J Allergy Clin
Immunol (2007) 120(6):1418–24. doi:10.1016/j.jaci.2007.06.040
48. Peng P, Yan Y, Keng S. Exosomes in the ascites of ovarian cancer patients:
origin and effects on anti-tumor immunity. Oncol Rep (2011) 25(3):749–62.
doi:10.3892/or.2010.1119
49. Tauro BJ, Greening DW, Mathias RA, Ji H, Mathivanan S, Scott AM, et al. Com-
parison of ultracentrifugation, density gradient separation, and immunoaffinity
capture methods for isolating human colon cancer cell line LIM1863-derived
exosomes. Methods (2012) 56(2):293–304. doi:10.1016/j.ymeth.2012.01.002
50. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand
kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the
killing. J Exp Med (1997) 186(12):2045–50. doi:10.1084/jem.186.12.2045
www.frontiersin.org April 2014 | Volume 5 | Article 144 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Klinker et al. B-LCL-derived FasL+ killer exosomes
51. de Souza N. Primer: genome editing with engineered nucleases. Nat Methods
(2012) 9(1):27. doi:10.1038/nmeth.1848
52. Joung JK, Sander JD. TALENs: a widely applicable technology for targeted
genome editing. Nat Rev Mol Cell Biol (2013) 14(1):49–55. doi:10.1038/
nrm3486
53. Münz C, Bickham KL, Subklewe M, Tsang ML, Chahroudi A, Kurilla MG, et al.
Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr
virus nuclear antigen EBNA1. J Exp Med (2000) 191(10):1649–60. doi:10.1084/
jem.191.10.1649
54. Théry C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of
exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell
Biol (2006) Chapter 3:Unit 322. doi:10.1002/0471143030.cb0322s30
55. Delecluse HJ, Hammerschmidt W. The genetic approach to the Epstein-Barr
virus: from basic virology to gene therapy. Mol Pathol (2000) 53(5):270–9.
doi:10.1136/mp.53.5.270
56. Yu Z, Lu J, Yu H, Yan Q, Zuo L, Li G. A precise excision of the complete Epstein-
Barr virus genome in a plasmid based on a bacterial artificial chromosome.
J Virol Methods (2011) 176(1–2):103–7. doi:10.1016/j.jviromet.2011.06.015
57. Thomson SA, Burrows SR, Misko IS, Moss DJ, Coupar BE, Khanna R. Target-
ing a polyepitope protein incorporating multiple class II-restricted viral epi-
topes to the secretory/endocytic pathway facilitates immune recognition by
CD4+ cytotoxic T lymphocytes: a novel approach to vaccine design. J Virol
(1998) 72(3):2246–52.
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 01 October 2013; paper pending published: 30 October 2013; accepted: 20
March 2014; published online: 02 April 2014.
Citation: Klinker MW, Lizzio V, Reed TJ, Fox DA and Lundy SK (2014)
Human B cell-derived lymphoblastoid cell lines constitutively produce Fas lig-
and and secrete MHCII+FasL+ killer exosomes. Front. Immunol. 5:144. doi:
10.3389/fimmu.2014.00144
This article was submitted to Alloimmunity and Transplantation, a section of the
journal Frontiers in Immunology.
Copyright © 2014 Klinker, Lizzio, Reed, Fox and Lundy. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Immunology | Alloimmunity and Transplantation April 2014 | Volume 5 | Article 144 | 10
